In this observational cohort study, sleep quality in post-COVID-19 patients was assessed using the Pittsburgh Sleep Quality Index (PSQI) questionnaire. This study aimed to examine aspects of sleep quality in patients who have undergone SARS-CoV-2 infection and if there is a pattern of progression or regression over time (6 months). We also observed and analyzed the results in order to identify any possible links between the severity of COVID-19 and sleep quality as measured by the PSQI questionnaire. The study group consisted of 65 adult patients with confirmed SARS-CoV-2 infection who were referred to a pulmonologist for evaluation. Sleep quality was impacted at a high rate in post-COVID-19 patients, quantified by a PSQI score ≥5. Out of 65 patients, 51% of them had scores greater than or equal to 5. Sleep was subjectively reported as unsatisfactory predominantly in mild and moderate COVID-19 patients. According to the PSQI score and a 6-month follow-up, many patients presented persistency in poor sleep quality. Investigation and individualized treatment of sleep disorders in post-COVID-19 patients should be part of the routine pneumological control, as improvement in sleep quality has an impact not only on the health but also on the psychological state of patients. Educating patients about the importance of sleep and sleep quality impairment should be a primary concern.

Bronchopulmonary cancer is the leading cause of cancer deaths globally. Rheumatoid arthritis is one of the risk factors for lung cancer, and those who use methotrexate have a higher risk of developing lung cancer. We present the case of an 80-year-old patient who is a former smoker and is known to have rheumatoid arthritis, being treated using methotrexate; they were brought by ambulance to the emergency room for coughing with ineffective expectoration, dyspnea on slight exertion, and right-lateral chest pain with onset about one month prior and progressive worsening. Imaging showed a 7 cm/6 cm LID tumorous lung formation with parietal invasion and C7 rib lysis, as well as diffuse fibrotic interstitial changes predominantly in the lower lobes. An ultrasound-guided transthoracic lung biopsy was performed, and histopathological examination established the diagnosis of invasive squamous cell lung carcinoma, G2. In conclusion, the chest pain interpreted by the patient as rheumatic pain delayed the diagnosis of lung cancer; the patient presented rather late to the hospital once respiratory failure set in.

This article reports the case of a patient with a gastric neoplasm and total gastrectomy, presenting with severe digestive intolerance, who developed peritoneal and pulmonary tuberculosis. Standard treatment could not be administered. Therefore, treatment was initiated with isoniazid and rifampicin suppositories, and intravenous levofloxacin and amikacin, with significant remission of the digestive symptomatology. Although treatment with rifampicin suppositories has demonstrated efficacy in tuberculosis, it is rarely used in practice. This case highlights the importance of individualizing tuberculosis treatment and demonstrates that rectal administration of isoniazid and rifampicin suppositories, combined with intravenous levofloxacin and amikacin, was successfully used to treat tuberculosis in a patient with severe digestive intolerance, highlighting a potential alternative regimen when standard oral therapy is not feasible.

Obstructive sleep apnea syndrome (OSAS) is a common disorder with established cardiovascular and metabolic risks. Positive airway pressure (PAP) therapy remains the standard of care; however, its long-term effectiveness is often limited by poor compliance and adherence. This study sought to explore clinical and device-related factors influencing PAP use, with emphasis on pressure variability in Auto-PAP users and comorbidities such as COPD. We performed a retrospective analysis of 359 patients with OSAS who were treated with CPAP, Auto-PAP, or BiPAP devices at the Marius Nasta Institute of Pneumology between January 2022 and July 2024. Compliance was measured as the proportion of days the device was used, whereas adherence was estimated through average nightly hours of use. Patient data were stratified by demographic, clinical, and device-related characteristics. Statistical testing included Chi-square, Wilcoxon rank-sum, and correlation analyses. Demographics did not significantly differ between compliant and non-compliant groups. Notably, Auto-PAP users with greater pressure variability (>10 cm H₂O) had significantly lower compliance (p = 0.001). Nasal mask preference was also associated with poorer compliance (p = 0.030). Multivariate models further revealed that atrial fibrillation reduced the likelihood of good adherence (OR = 0.319, 95% CI 0.137–0.746). These results highlight the importance of monitoring pressure variability, device type, and comorbidities to personalize PAP therapy and improve long-term outcomes.